Clinical Trial: Semaglutide Versus Placebo in <scp>NIT</scp> ‐Assessed <scp>MASH</scp> —A Multicenter Randomised Placebo‐Controlled Trial ( <scp>SAMARA</scp> )

A NIT-based approach to identify at-risk MASH patients for semaglutide treatment is feasible and effective. This study provides RCT data showing that FAST, ALT, AST and MRI-PDFF can be used to monitor treatment response.